Latest Alkermes Plc (ALKS) Headlines Nanotechno
Post# of 97
Posted On: 03/12/2014 5:40:00 PM
Latest Alkermes Plc (ALKS) Headlines
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Regado Rises on REG1 Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 1:16PM CDT
Shares of Regado soared 38.1% and also touched a 52-week high.
Alexion Lifts 2014 View, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 12:42PM CDT
Alexion lifts outlook following French reimbursement deal on Soliris.
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Additional Positive Data on Omeros Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 5:50PM CDT
Omeros announced additional positive results from its phase IIa study on OMS824, for the treatment of schizophrenic patients.
NewLink Genetics' Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 12:36PM CDT
Share prices of NewLink Genetics fell 16.2% after the committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas.
Biogen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 10:40AM CDT
Biogen upgraded to Zacks Rank #1 (Strong Buy)
Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:39AM CDT
Aegerion Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:10AM CDT
Emergent had a strong quarter with both revenues and earnings coming above expectations.
Emergent BioSolutions (EBS) Soars: Stock Rises 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:51AM CDT
Emergent BioSolutions, Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Alcobra Gains IND Clearance for MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:40PM CST
Alcobra's IND application for Metadoxine Extended Release (MDX) has been cleared by the U.S. FDA recently.
Pipeline Progress at Alkermes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 3:30PM CST
Alkermes announced that it has initiated a pivotal program to evaluate ALKS 5461.
Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.
Regulatory Update on Cubist Pharma's Tedizolid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 4:20PM CST
The EMA accepted the MAA for Cubist Pharma's tedizolid phosphate.
Rigel Rises on Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:40AM CST
Rigel Pharma's 4Q13 loss of 19 cents per share was narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of 30 cents per share
Osiris Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:10AM CST
Osiris is focusing on its Biosurgery products which have been gaining traction over the past few quarters.
Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:54AM CST
Synta Pharmaceuticals Corp. (SNTA) saw a big move last session, reversing the recent trend for SNTA as the stock is now up around 8.4% in the past one-month time frame.
Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder
Business Wire - Thu Mar 06, 6:00AM CST
Alkermes plc (NASDAQ: ALKS) today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The comprehensive pivotal program, named FORWARD (Focused On Results With A Rethinking of Depression), includes a total of 12 studies, including three core phase 3 efficacy studies and nine supportive studies. The first FORWARD study, evaluating the onset of clinical effect, safety and tolerability of ALKS 5461 in approximately 60 patients with MDD, has begun, and the three core efficacy studies are expected to begin in mid 2014.
Update on Alexion's Soliris - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 11:00AM CST
NICE has asked Alexion to clarify Soliris' high coast.
Narrower-than-Expected Q4 Loss at GTx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:50AM CST
GTx, reported fourth quarter 2013 net loss per share of 12 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Regado Rises on REG1 Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 1:16PM CDT
Shares of Regado soared 38.1% and also touched a 52-week high.
Alexion Lifts 2014 View, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 12:42PM CDT
Alexion lifts outlook following French reimbursement deal on Soliris.
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Additional Positive Data on Omeros Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 5:50PM CDT
Omeros announced additional positive results from its phase IIa study on OMS824, for the treatment of schizophrenic patients.
NewLink Genetics' Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 12:36PM CDT
Share prices of NewLink Genetics fell 16.2% after the committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas.
Biogen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 10:40AM CDT
Biogen upgraded to Zacks Rank #1 (Strong Buy)
Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:39AM CDT
Aegerion Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:10AM CDT
Emergent had a strong quarter with both revenues and earnings coming above expectations.
Emergent BioSolutions (EBS) Soars: Stock Rises 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:51AM CDT
Emergent BioSolutions, Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Alcobra Gains IND Clearance for MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:40PM CST
Alcobra's IND application for Metadoxine Extended Release (MDX) has been cleared by the U.S. FDA recently.
Pipeline Progress at Alkermes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 3:30PM CST
Alkermes announced that it has initiated a pivotal program to evaluate ALKS 5461.
Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.
Regulatory Update on Cubist Pharma's Tedizolid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 4:20PM CST
The EMA accepted the MAA for Cubist Pharma's tedizolid phosphate.
Rigel Rises on Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:40AM CST
Rigel Pharma's 4Q13 loss of 19 cents per share was narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of 30 cents per share
Osiris Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:10AM CST
Osiris is focusing on its Biosurgery products which have been gaining traction over the past few quarters.
Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:54AM CST
Synta Pharmaceuticals Corp. (SNTA) saw a big move last session, reversing the recent trend for SNTA as the stock is now up around 8.4% in the past one-month time frame.
Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder
Business Wire - Thu Mar 06, 6:00AM CST
Alkermes plc (NASDAQ: ALKS) today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The comprehensive pivotal program, named FORWARD (Focused On Results With A Rethinking of Depression), includes a total of 12 studies, including three core phase 3 efficacy studies and nine supportive studies. The first FORWARD study, evaluating the onset of clinical effect, safety and tolerability of ALKS 5461 in approximately 60 patients with MDD, has begun, and the three core efficacy studies are expected to begin in mid 2014.
Update on Alexion's Soliris - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 11:00AM CST
NICE has asked Alexion to clarify Soliris' high coast.
Narrower-than-Expected Q4 Loss at GTx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:50AM CST
GTx, reported fourth quarter 2013 net loss per share of 12 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents
(0)
(0)Alkermes plc (ALKS) Stock Research Links
Scroll down for more posts ▼